Avivagen Inc.
VIVXF
$0.00
$0.000.00%
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 30.40K | 57.40K | 49.00K | 399.00K | 37.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.40K | 57.40K | 49.00K | 399.00K | 37.80K |
| Cost of Revenue | 12.50K | 39.00K | 26.20K | 229.10K | 20.70K |
| Gross Profit | 17.80K | 18.30K | 22.80K | 169.80K | 17.00K |
| SG&A Expenses | 332.00K | 589.70K | 533.20K | 989.30K | 1.15M |
| Depreciation & Amortization | 4.00K | 11.30K | 15.10K | 15.30K | 15.80K |
| Other Operating Expenses | -- | -5.10K | -5.60K | -21.00K | -3.90K |
| Total Operating Expenses | 348.50K | 635.00K | 568.90K | 1.21M | 1.18M |
| Operating Income | -318.20K | -577.70K | -519.90K | -813.80K | -1.15M |
| Income Before Tax | -699.30K | -919.10K | -856.10K | -983.00K | -1.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -699.30K | -919.10K | -856.10K | -983.00K | -1.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -699.30K | -919.10K | -856.10K | -983.00K | -1.48M |
| EBIT | -318.20K | -577.70K | -519.90K | -813.80K | -1.15M |
| EBITDA | -314.20K | -573.70K | -515.90K | -809.80K | -1.13M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 77.69M | 77.47M | 77.19M | 45.14M | 63.19M |
| Average Diluted Shares Outstanding | 77.69M | 77.47M | 77.19M | 45.14M | 63.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |